Back to search

Article

Mucosal Immune Response after the Booster Dose of the <i>BNT162b2</i> COVID-19 Vaccine

2022-06-08

Abstract excerpt

Background: To date, there are no data regarding the mucosal immune response after the BNT162b2-booster vaccination.<br><br>Methods: Samples of both serum and saliva of 50 healthcare workers were collected at the day of the booster dose and after two weeks. Anti-S1-protein IgG and IgA antibody titres and the neutralizing antibodies against the Wuhan wild-type Receptor-Binding Domain in both serum and saliva were m...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
891289b9-a477-53a3-8593-fb6984fd307a
DOI
10.2139/ssrn.4131248
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Mucosal Immune Response after the Booster Dose of the <i>BNT162b2</i> COVID-19 VaccineDOI 10.2139/ssrn.4131248
Mucosal Immune Response in BNT162b2 COVID-19 Vaccine RecipientsSemantic proximity
Evaluation of the systemic and mucosal immune response induced by COVID-19 and the BNT162b2 mRNA vaccine for SARS-CoV-2Semantic proximity
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after the third dose of BNT162b2 in healthy adolescentsSemantic proximity
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workersSemantic proximity
Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA VaccineSemantic proximity
Bivalent BNT162b2mRNA original/Omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared to the monovalent COVID-19 boosterSemantic proximity
Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trialSemantic proximity
A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boostingSemantic proximity
Third dose vaccine With BNT162b2 and its response on Long COVID after Breakthrough infectionsSemantic proximity
Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) VaccineSemantic proximity
Extended interval BNT162b2 vaccination enhances peak antibody generation in older peopleSemantic proximity
Protection against omicron severe disease 0-7 months after BNT162b2 boosterSemantic proximity
Select a neighboring publication to make it the new centre.